Simple Summary Glioblastoma (GBM) is the most common adult brain cancer. Despite
extensive treatment protocols, all glioblastomas are eventually fatal. Photodynamic therapy …

Triggering receptor expressed on myeloid cells 2 (TREM2) plays important roles in brain
microglial function in neurodegenerative diseases, but the role of TREM2 in the GBM TME …

Glioma, the most common primary malignant tumor in the central nervous system (CNS),
lacks effective treatments, and> 60% of cases are glioblastoma (GBM), the most aggressive …

Chimeric antigen receptor (CAR) T cell therapy in glioblastoma faces many challenges
including insufficient CAR T cell abundance and antigen-negative tumor cells evading …

Glioblastoma (GBM) is a common and devastating primary brain tumor, with median survival
of 16–18 months after diagnosis in the setting of substantial resistance to standard-of-care …

Background Myeloid cells comprise up to 50% of the total tumor mass in glioblastoma (GBM)
and have been implicated in promoting tumor progression and immunosuppression …

The abscopal effect is a phenomenon wherein localised therapy on the primary tumour
leads to regression of distal metastatic growths. Interestingly, various pre-clinical studies …

Immunotherapy is a promising therapeutic domain for the treatment of gliomas. However,
clinical trials of various immunotherapeutic modalities have not yielded significant …

Simple Summary The urgent need for novel therapies for glioblastoma (GBM) treatment may
be met through an increased understanding of immune escape and improved …

Recent advances in cancer biology and therapeutics have underscored the importance of
preclinical models in understanding and treating cancer. Nevertheless, current models often …